Drug-Drug Interactions (DDI) Archives

Announcement

Certara Launches DIDB® Concomitant Meds Navigator, Extending Leadership in Drug Interaction Science

Meet DIDB Concomitant Meds Navigator—an evidence-based tool to identify contraindicated or monitored co-medications and manage…

CertaraSeptember 22, 2025

Fact Sheet

Drug Interaction Database (DIDB ®)

Optimize DDI knowledge throughout drug development

CertaraSeptember 19, 2025

Announcement

Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool

RADNOR, Pa. – September 17, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in…

CertaraSeptember 17, 2025

Blog

Replacing Traditional TQT Studies with Model-Based Concentration-QTc (C-QTc) Analysis for Cardiovascular Safety in Drug Development

Learn how our experts use concentration-QTc (C-QTc) analysis to replace costly TQT studies, streamline QT…

CertaraAugust 6, 2025

On-Demand Webinar

De-risking DDI Management during Clinical Trials: Introducing DIDB’s Concomitant Meds Navigator

Watch the on-demand presentation covering how the DIDB® Concomitant Meds Navigator empowers clinical development teams…

CertaraAugust 5, 2025

Press Release

Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling

Certara announces that EMA has formally qualified the Simcyp® Simulator for use in regulatory submissions…

CertaraAugust 4, 2025

Conference

EACPT 2025 CONGRESS

- - Booth

Danielle PillsburyJune 10, 2025

Blog

What are the most common in vitro drug-drug interaction study gaps?

Certara drug interaction science experts share data and experimental design gaps commonly found in in…

CertaraJune 9, 2025

On-Demand Webinar

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions

Director, Clinical Pharmacology, ORIC Pharmaceuticals SVP, Head of Simcyp PBPK Modeling Services, Certara Director, PBPK…

CertaraApril 21, 2025

Blog

Measuring metabolites in index clinical DDI studies

February 7, 2025A key drug development safety consideration is whether the drug candidate will interact…

CertaraFebruary 7, 2025

Drug-Drug Interactions (DDI)

Certara Launches DIDB® Concomitant Meds Navigator, Extending Leadership in Drug Interaction Science

Drug Interaction Database (DIDB ®)

Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool

Replacing Traditional TQT Studies with Model-Based Concentration-QTc (C-QTc) Analysis for Cardiovascular Safety in Drug Development

De-risking DDI Management during Clinical Trials: Introducing DIDB’s Concomitant Meds Navigator

Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling

EACPT 2025 CONGRESS

What are the most common in vitro drug-drug interaction study gaps?

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions

Measuring metabolites in index clinical DDI studies

Newsletter sign up

Quick links

Solutions

Contact